Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4196)	5/4/1998 3:24:00 PM
From: Izzy	Read Replies (4) \| Respond to of 6136

OK Steve and others: I just talked to someone in AGPH research dep't and AG3340 (MMPI) IS an angiogenesis inhibitor drug and it's beyond just testing in mice (re: ENMD "drug," which, I think the CEO said, or implied, today on CNBC would not get into clinical trials for 3+ yrs, if ever; someone correct me if I'm wrong). AGPH is way beyond that stage and AG3340 is already in clinical trials. Sorry, I could not find out anything further about the progress of the AG3340 trials. AGPH is just a great company and is very far ahead of the pack. Yet, ENMD is up 39+ today (I would have liked to make that kind of profit in one day). FWIW, I'm sticking with AGPH, an established money-making company with a blockbuster drug on the market and a terrific pipeline in progress, including an angiogenesis inhibiting drug. PS: Everyone don't jump on me for providing this info (and don't plaster it all over the internet) as I am just stating what I understood the conversation to be (verify for yourself). It has just been my impression that AGP3340 is an angiogenesis inhibiting drug, and apparently I am correct. So, why doesn't AGPH go up 39+ in one day? This company doesn't brag about how well it's doing, IMO. It's just a good, honest company that is making honest money.